KLDO
Kaleido Biosciences, Inc. [KLDO] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
KLDO Stock Summary
In the News
KLDO Financial details
Company Rating
-
Market Cap
4.26K
Income
0
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
76
Optionable
No
Shortable
Yes
Earnings
22 May 2023
P/E
0
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
-
P/FCF
-
Quick Ratio
1.3
Current Ratio
1.43
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
0
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-186%
ROE
-600%
ROC
-4.29%
Gross Margin
100%
Oper. Margin
-7941%
Profit Margin
-8448%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.0E-5-0.03
52W High
-
52W Low
-
RSI
50.15
Rel Volume
72.68
Avg Volume
206
Volume
14.97K
Perf Week
0%
Perf Month
0%
Perf Quarter
0%
Perf Half Y
0%
-
-
-
-
Beta
36.971
-
-
Volatility
0%, 0%
Prev Close
-
Price
0.0001
Change
0%
Company Profile
- Volume Average 206
- Market Capitalization 4.26K
- Employee 76
- CEO Ms. Kimberly Hocknell
- Headquarters Lexington,MA,US
- IPO Date 2019-02-28
-
Website
https://kaleido.com 
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
